Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]
PeerJLi Z +14 more
europepmc +1 more source
The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta-Analysis and Trial Sequential Analysis. [PDF]
Cardiovasc TherWang S, Li C, Fan D.
europepmc +1 more source
Related searches:
Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
Advances in Experimental Medicine and Biology, 2020Plasma levels of cholesterol, especially low-density lipoprotein cholesterol (LDL-C), are positively correlated with the risk of cardiovascular disease. Buildup of LDL in the intima promotes the formation of foam cells and consequently initiates atherosclerosis, one of the main underlying causes of cardiovascular disease. Hepatic LDL receptor (LDLR) is
Shoudong, Guo +3 more
openaire +3 more sources
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Neuroscience and Biobehavioral Reviews, 2023The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein product have been widely studied for their role in cholesterol and lipid metabolism.
A. Bell +3 more
semanticscholar +1 more source
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Heart, 2022Objective To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy. Methods This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo ...
Jing Li +16 more
semanticscholar +1 more source
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.
Biochimica et biophysica acta. Reviews on cancer, 2021Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel pharmacological target for hypercholesterolemia and associated cardiovascular diseases owing to its function to mediate the degradation of low-density lipoprotein receptor (LDLR)
Anindita Bhattacharya +3 more
semanticscholar +1 more source
Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review
Combinatorial Chemistry & High Throughput Screening, 2023Abstract: PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that helps to reduce cardiovascular events. This clinical result is attributable primarily to the crucial involvement of PCSK9 in regulating the low-density lipoprotein cholesterol level.
Sonia Singh +4 more
openaire +2 more sources
Proprotein convertase subtilisin/kexin type 9 inhibition
Current Opinion in Lipidology, 2012There are now ample data that demonstrate that inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) can safely lower LDL cholesterol synergistically with statins. Considering that PCSK9 was first identified less than a decade ago, the last few years have shown rapid and remarkable advancements in our understanding and knowledge of the ...
David A, Marais +4 more
openaire +2 more sources
Phytochemical investigation of the methanol extract of the aerial parts of Salvia plebeia aided by a proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA expression screening assay in HepG2 cells led to the identification of 19 compounds including ...
Piseth Nhoek +8 more
semanticscholar +1 more source
Proprotein convertase subtilisin/kexin type 9
Current Opinion in Cardiology, 2018This review describes the pivotal role of genetic insights and technologies in the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rapid development of PCSK9 inhibitors - a revolutionary new class of lipid-lowering agents.PCSK9 was discovered as a the third gene implicated in familial hypercholesterolemia. Population genetics
Robert M, Stoekenbroek +1 more
openaire +2 more sources